Cremers Eline M P, Alhan Canan, Westers Theresia M, Ossenkoppele Gert J, van de Loosdrecht Arjan A
Department of Hematology, VU University Medical Center, Cancer Center Amsterdam (VUmc CCA), Amsterdam, The Netherlands.
Department of Hematology, VU University Medical Center, Cancer Center Amsterdam (VUmc CCA), Amsterdam, The Netherlands.
Best Pract Res Clin Haematol. 2015 Mar;28(1):14-21. doi: 10.1016/j.beha.2014.11.003. Epub 2014 Nov 11.
Myelodysplastic syndromes is a heterogeneous group of bone marrow diseases ranging from low risk to high risk subtypes that may rapidly evolve to acute myeloid leukemia. Flow cytometry (FCM) is added as a recommended tool for diagnostic purposes in MDS. In recent studies FCM has also shown applicable to predict prognosis and treatment response. This review summarizes current data about the diagnostic, prognostic and therapeutic value of FCM in MDS. The high sensitivity of FCM in the detection of dysplasia in myelo-/monocytic and erythroid cell lineages makes it a valuable tool to distinguish possible clonal causes of cytopenia(s) from non-clonal causes, and to detect multi-lineage dysplasia in addition to cytomorphology. The utility of FCM in prediction of treatment response is promising. Therefore, FCM is an essential tool in standard diagnostic strategies in case of suspected MDS, and ready for general application.
骨髓增生异常综合征是一组异质性的骨髓疾病，涵盖从低风险到高风险的亚型，可能迅速演变为急性髓系白血病。流式细胞术（FCM）被作为诊断MDS的推荐工具。在最近的研究中，FCM也已显示适用于预测预后和治疗反应。本综述总结了有关FCM在MDS中的诊断、预后和治疗价值的当前数据。FCM在检测髓系/单核细胞系和红系细胞系发育异常方面具有高敏感性，这使其成为一种有价值的工具，可用于区分血细胞减少的可能克隆性原因与非克隆性原因，并除细胞形态学外还能检测多系发育异常。FCM在预测治疗反应方面的效用很有前景。因此，在疑似MDS的情况下，FCM是标准诊断策略中的一项重要工具，且已准备好广泛应用。
